Biotech 2050 Podcast

Chris is Sr. Vice President, Technical Operations at Blueprint Medicines. He has over 25 years of commercial and clinical manufacturing experience in the biopharmaceutical industry and has been fortunate to help develop and commercialize numerous oncology medicines. He has been in his current role since October 2017.

Carl P. Decicco is a biopharmaceutical veteran with over 30+ years of experience in the industry. Over the course of his career, Carl has played a central role in the advancement of more than 200 compounds into clinical trials and the approval of more than 20 drugs across multiple therapeutic areas. He’s authored/Co-Authored more than 100 scientific papers in peer reviewed journals and is listed as an inventor on 26 patents.

Dr. Florian Wegener is the co-founder and CEO of ZAGENO, an award-winning online marketplace serving the needs of research scientists. He is also a board-certified physician.

Raman is the founder and global president of ramarketing - an international design, digital and PR agency that's in the business of helping ambitious contract service companies operating in the global biotech and pharmaceutical outsourcing sector get noticed.

In this episode, guest Kevin Bittorf, founder of the Advancing Drug Development Forum and Don Dickerson sat down with host Alok Tayi to discuss trends in modern manufacturing and pharmaceutical environments. Kevin Bittorf is an accomplished Senior Executive and Consultant with demonstrated success and a proven track record in pharmaceutical development, technical Innovation, and IoT.

Jon Hennek co-leads the Systems Innovation Team at Indigo Ag. He co-founded the team—whose mission is to create a vision for what agriculture could look like in the distant future and develop a strategy for the Indigo model to dramatically accelerate its adoption—in 2017 while at Flagship Pioneering.

Sven Karlsson is the co-founder, chief operating officer and chief business officer of Platelet BioGenesis. In this episode of Biotech2050, Sven talks about his background, how he came to founding Platelet BioGenesis and the problems he and his team are trying to solve with the world's only method of producing clinical-grade human platelets from induced pluripotent stem cells.

Dr. Jo Viney is an entrepreneurial scientist and experienced biotech executive. A self-described “drug-hunter”, she has successfully advanced a number of programs into the clinic. She is Co-Founder, President and CSO of Pandion Therapeutics, a startup company in Cambridge, MA focused on developing new therapies for treating autoimmune and inflammatory diseases. On this episode of Biotech2050, Jo talked about her journey to the biotech industry and how she came to founding Pandion Therapeutics, successfully bringing a drug to market, women in leadership, and the importance of diversity in biotech.

John Keilty is the Chief Data Sciences Officer at Decibel Therapeutics and a Strategic advisor at Third Rock Ventures. He is a biologist and bioinformatics guy by training and has been active in the biotech space for over two decades. In his career, John has been responsible for building out genomix, and genetics capabilities for early stage biotech companies. In this episode of Biotech 2050, John goes through his journey into the biotech industry and the work he’s doing at Decibel Therapeutics and Third Rock Ventures.

In this inaugural episode of Biotech2050, hosts Alok Tayi and Rahul Chatuverdi sits down with Lee Cooper, a seasoned biotech entrepreneur, lawyer, patient advocate, founder of Enlight Bio and the nonprofit Institute for Genetic Disease Prevention to talk about the importance of patient centricity in today’s modern biotech. Cooper writes and speaks on health innovation and bioethics. He has a JD and MBA from Columbia University, and a BA in Religion and Public Policy from Dartmouth College. Today, he talked about his journey to the Biotech industry and how he came to founding Enlight Bio. Apple: 084248